Staphylococcus aureus: Current State of Prevalence, Impact, and Vaccine Development

E-ISSN： 1873-4286|21|16|2131-2135

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.21, Iss.16, 2015-05, pp. : 2131-2135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Staphylococcus aureus Vaccine Conjugate Nabi: Nabi-StaphVAX, StaphVAX

By Limited A.I.

Drugs in R&D, Vol. 4, Iss. 6, 2003-01 ,pp. : 383-385

Adis International

Access to resources Recommend Favorite

Virulence Factor Targeting of the Bacterial Pathogen Staphylococcus aureus for Vaccine and Therapeutics

Current Drug Targets, Vol. 19, Iss. 2, 2018-01 ,pp. : 111-127

Bentham Science Publishers

Access to resources Recommend Favorite

Epidemiology and Economic Impact of Meticillin-Resistant Staphylococcus aureus: Review and Analysis of the Literature

By Shorr Andrew F.

PharmacoEconomics, Vol. 25, Iss. 9, 2007-01 ,pp. : 751-768

Adis International

Access to resources Recommend Favorite

Rifampicin/vancomycin: Development of rifampicin resistance in methicillin-resistant Staphylococcus aureus infection in an infant: case report

Reactions Weekly, Vol. 1, Iss. 1308, 2010-01 ,pp. : 29-30

Adis International

Access to resources Recommend Favorite

Shigella Vaccine Development: Prospective Animal Models and Current Status

Current Pharmaceutical Biotechnology, Vol. 14, Iss. 10, 2013-11 ,pp. : 903-912

Bentham Science Publishers

Access to resources Recommend Favorite